Main Luck Pharmaceuticals

Shenzhen Main Luck Pharmaceuticals, an international capital alliance drawing resources from China (Shenzhen Accord Pharmaceutical Co., Ltd.), Japan (Miroku Co., Ltd.), and Hong Kong (Man Luen Hong Limited). An international platform gathering professional technology, keeping pace with global pharmaceutical development, with innovation and efficiency as the inexhaustible foundation of corporate progress. Since its founding in 1990, it has soared with annual growth of over 30%. With outstanding achievements in the comprehensive ranking of anti-tumor production enterprises nationwide, it has emerged as a leader in the industry, forging an outstanding international pharmaceutical enterprise with a spirit of constant innovation.
To date, Main Luck has acquired a series of key new products including pirarubicin, aclarubicin, doxorubicin, daunorubicin, docetaxel, vincristine, bleomycin, Lastet, mesna, ifosfamide, and more. It has formed a systematic industrial chain with annual production capacity of 5 million vials of lyophilized powder injections, 50 million ampoules of small-volume injections, 10 million capsules, and high-grade, precision, and advanced technical standard raw materials.
Relying on scientific research institutions across China, Japan, Hong Kong and beyond, as well as exchange visits with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, the Sichuan Industrial Institute of Antibiotics, the National Engineering Research Center for Pharmaceutical Formulation, the Pharmaceutical Engineering Research Institute of the National University of Singapore, Vanderbilt University in the United States, Kumamoto University in Japan, Nippon Kayaku and other renowned international companies, it conducts extensive cooperation in new product research and production. While continuously improving and upgrading its leading products, Main Luck Pharmaceuticals continues to advance into biomedical genetic engineering drugs, anti-tumor adjuvant drugs, and newer fields. It focuses on developing high-tech, world-class genetic engineering new drugs such as anti-CD20 monoclonal antibodies and CM101 that inhibits tumor angiogenesis; simultaneously it explores new formulation fields, building cutting-edge technology platforms for injectable sustained-release microspheres, liposomes, colon-targeted release, and more, comprehensively promoting product upgrading and technological progress in China's pharmaceutical industry. Main Luck Pharmaceuticals has rapidly advanced from single-category product manufacturing into a diversified product R&D-oriented enterprise.
In the era of rapidly changing information technology, Main Luck Pharmaceuticals, with the purpose of actively promoting the development of human health, has established a service network covering 29 provinces, municipalities, and autonomous regions nationwide with strong academic capabilities, building a bridge and bond for communication between the enterprise and its customers. It regularly organizes and participates in high-level academic seminars in China and internationally, exchanging and disseminating modern medical information. Working hand in hand with domestic and international oncology experts, it conducts rigorous multi-center clinical research, tackling and solving frontier medical topics. It also strengthens cooperation and exchange with modern core academic journals, sharing medical treatment and research results. The establishment of various platforms has powerfully promoted the development of medical standards in its field.
While domestic sales continue to expand, its high-quality products have also gained broad international recognition. Currently, Main Luck products are exported to the Middle East, Southeast Asia, South America, Eastern Europe, and other countries, achieving formulation product exports at an early stage.
Rich accumulation and an efficient team have successfully won deep cooperation from numerous internationally renowned enterprises, thereby laying a solid foundation for Main Luck Pharmaceuticals to continuously scale the heights of pharmaceutical technology.
Cooperation inspires the driving force for progress. Sharing builds the starting point for takeoff. Main Luck Pharmaceuticals, with its focused spirit of promoting national pharmaceuticals and being highly responsible for life, builds a solid platform with integrity and innovation, and with real-time effective resource integration capabilities, closely follows the professional direction of international industry development, actively expanding new product development and research in high-precision fields, deepening and expanding core expertise with excellent and efficient Main Luck speed, maintaining strategic, capability, and industry development momentum, broadly attracting in-depth cooperation globally, planning ideal career paths for employees, creating opportunities for mutual development with partners, pursuing sustainable growth and long-term success, and becoming an internationally competitive industrial holding group.
Focus on life and health, focus on Main Luck Pharmaceuticals. For more details, please visit
II. Corporate Honors:
1991.04 Member of Shenzhen Association of Enterprises with Foreign Investment.
1992.10 Member of Shenzhen Pharmaceutical Industry Association.
2001.12 Awarded the title of "Civilized Enterprise" by the CPC Shenzhen Municipal Committee and Shenzhen Municipal Government.
2003.02 Shenzhen High-tech Enterprise.
2003.08 "Hydroxycamptothecin Injection" recognized as a National Key New Product of 2002.
2004 Awarded the "Science and Technology Progress Award" by Shenzhen SME Development Promotion Association.
2003-2008 For six consecutive years, rated as "Shenzhen Futian District Top 100 VAT Taxpayers" by the Shenzhen Tax Bureau and Shenzhen Futian District People's Government.
2005 Awarded "Shenzhen Batch 6 High-tech Projects - Aclarubicin, Pirarubicin, Hydroxycamptothecin" by Shenzhen Science and Technology Information Bureau.
2005.09 Awarded the title of "2005 Top 100 Enterprises in China's Pharmaceutical Industry."
2006.05 Awarded the "Science and Technology Innovation Award" by Shenzhen SME Development Promotion Association.
2008.12 Established Enterprise Technology Center, awarded "Shenzhen Municipal-level Research and Development Center (Technology Center Category) Certificate."
2008.12 Awarded "High-tech Enterprise Certificate."
2009.01 Docetaxel API and its injection, Pirarubicin Hydrochloride for Injection, and Hydroxycamptothecin each received "Shenzhen Independent Innovation Product Certification."
2009.03 Standing Council Member Unit of Guangdong Anti-Cancer Association.
2010.03 Shenzhen Growth-oriented Small and Medium Industrial Enterprise.